ANGPTL4 and psoriasis: More specifically, we identified PEDF, MDC and ANGPTL4 from the same pharmacodynamic pattern as IL-17A and KLK-7, for which the combined rate of decline between Week 4 and 16 could differentiate apremilast clinical responses in psoriasis.